Neuphoria Therapeutics (NASDAQ:NEUP) Announces Earnings Results, Misses Expectations By $0.21 EPS

Neuphoria Therapeutics (NASDAQ:NEUP) issued its quarterly earnings data on Tuesday. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21), Zacks reports.

Neuphoria Therapeutics Price Performance

Neuphoria Therapeutics stock remained flat at $4.05 during midday trading on Tuesday. The company’s stock had a trading volume of 13,108 shares, compared to its average volume of 37,245. Neuphoria Therapeutics has a 12 month low of $3.64 and a 12 month high of $21.40. The company’s fifty day simple moving average is $4.00 and its 200 day simple moving average is $7.27. The company has a market capitalization of $21.78 million, a price-to-earnings ratio of -0.83 and a beta of 0.52.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen lowered Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. HC Wainwright lowered their target price on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, December 5th. Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $21.00.

Institutional Trading of Neuphoria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in NEUP. Commonwealth Equity Services LLC purchased a new stake in Neuphoria Therapeutics during the fourth quarter worth about $43,000. Persistent Asset Partners Ltd lifted its position in shares of Neuphoria Therapeutics by 173.1% during the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares during the period. Geode Capital Management LLC lifted its position in shares of Neuphoria Therapeutics by 33.3% during the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after acquiring an additional 4,325 shares during the period. Diadema Partners LP boosted its stake in shares of Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after acquiring an additional 28,548 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Neuphoria Therapeutics in the 3rd quarter worth approximately $216,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.